191 related articles for article (PubMed ID: 30214535)
1. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway.
Shen T; Xu B; Lei T; Chen L; Zhang C; Ni Z
Exp Ther Med; 2018 Oct; 16(4):3121-3128. PubMed ID: 30214535
[TBL] [Abstract][Full Text] [Related]
2. Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats.
Akaslan SB; Degertekin CK; Yilmaz G; Cakir N; Arslan M; Toruner FB
Metab Syndr Relat Disord; 2013 Aug; 11(4):243-50. PubMed ID: 23544853
[TBL] [Abstract][Full Text] [Related]
3. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
4. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease
Li CX; Gao JG; Wan XY; Chen Y; Xu CF; Feng ZM; Zeng H; Lin YM; Ma H; Xu P; Yu CH; Li YM
World J Gastroenterol; 2019 Sep; 25(34):5120-5133. PubMed ID: 31558861
[TBL] [Abstract][Full Text] [Related]
5. A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression.
Hwang HJ; Jung TW; Kim BH; Hong HC; Seo JA; Kim SG; Kim NH; Choi KM; Choi DS; Baik SH; Yoo HJ
Biochem Pharmacol; 2015 Nov; 98(1):157-66. PubMed ID: 26297911
[TBL] [Abstract][Full Text] [Related]
6. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
Liou CJ; Wei CH; Chen YL; Cheng CY; Wang CL; Huang WC
Cell Physiol Biochem; 2018; 49(5):1870-1884. PubMed ID: 30235452
[TBL] [Abstract][Full Text] [Related]
7. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.
Ideta T; Shirakami Y; Miyazaki T; Kochi T; Sakai H; Moriwaki H; Shimizu M
Int J Mol Sci; 2015 Dec; 16(12):29207-18. PubMed ID: 26670228
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl-Peptidase 4 Inhibitor Sitagliptin Ameliorates Hepatic Insulin Resistance by Modulating Inflammation and Autophagy in ob/ob Mice.
Zheng W; Zhou J; Song S; Kong W; Xia W; Chen L; Zeng T
Int J Endocrinol; 2018; 2018():8309723. PubMed ID: 30123267
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
10. Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance.
Kim HY; Park SY; Lee MH; Rho JH; Oh YJ; Jung HU; Yoo SH; Jeong NY; Lee HJ; Suh S; Seo SY; Cheong J; Jeong JS; Yoo YH
J Hepatol; 2015 Aug; 63(2):477-85. PubMed ID: 25646886
[TBL] [Abstract][Full Text] [Related]
11. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease.
Xiao Z; Chu Y; Qin W
Life Sci; 2020 Sep; 256():117997. PubMed ID: 32585242
[TBL] [Abstract][Full Text] [Related]
12. Amelioration of diet-induced metabolic syndrome and fatty liver with sitagliptin via regulation of adipose tissue inflammation and hepatic Adiponectin/AMPK levels in mice.
Prakash S; Rai U; Kosuru R; Tiwari V; Singh S
Biochimie; 2020 Jan; 168():198-209. PubMed ID: 31715215
[TBL] [Abstract][Full Text] [Related]
13. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
[TBL] [Abstract][Full Text] [Related]
14. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
Long JK; Dai W; Zheng YW; Zhao SP
Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
[TBL] [Abstract][Full Text] [Related]
15. Sake lees extract improves hepatic lipid accumulation in high fat diet-fed mice.
Kubo H; Hoshi M; Matsumoto T; Irie M; Oura S; Tsutsumi H; Hata Y; Yamamoto Y; Saito K
Lipids Health Dis; 2017 Jun; 16(1):106. PubMed ID: 28578672
[TBL] [Abstract][Full Text] [Related]
16. Troxerutin improves hepatic lipid homeostasis by restoring NAD(+)-depletion-mediated dysfunction of lipin 1 signaling in high-fat diet-treated mice.
Zhang ZF; Fan SH; Zheng YL; Lu J; Wu DM; Shan Q; Hu B
Biochem Pharmacol; 2014 Sep; 91(1):74-86. PubMed ID: 25026599
[TBL] [Abstract][Full Text] [Related]
17. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
Park EJ; Kim YM; Kim HJ; Jang SY; Oh MH; Lee DH; Chang KC
Eur J Pharmacol; 2016 Oct; 788():200-209. PubMed ID: 27343380
[TBL] [Abstract][Full Text] [Related]
18. Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet.
Liou CJ; Lee YK; Ting NC; Chen YL; Shen SC; Wu SJ; Huang WC
Cells; 2019 May; 8(5):. PubMed ID: 31083505
[TBL] [Abstract][Full Text] [Related]
19. Vitexin alleviates non-alcoholic fatty liver disease by activating AMPK in high fat diet fed mice.
Inamdar S; Joshi A; Malik S; Boppana R; Ghaskadbi S
Biochem Biophys Res Commun; 2019 Oct; 519(1):106-112. PubMed ID: 31472955
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice.
Onoyama T; Koda M; Okamoto T; Kishina M; Matono T; Sugihara T; Murawaki Y
Mol Med Rep; 2015 Nov; 12(5):6895-902. PubMed ID: 26397061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
